Xilio Therapeutics (XLO) Total Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics has reported Total Non-Current Liabilities for 6 years, with the latest figure at $64.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $64.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.7 million (changed N/A YoY) and the FY2025 annual result came in at $89.9 million, changed N/A from the prior year.
• Total Non-Current Liabilities retreated to $64.7 million in Q1 2026 per XLO's latest filing, from $89.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $89.9 million in Q4 2025 and troughed at $25.0 million in Q2 2023.
• A 4-year average of $51.1 million and a median of $33.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities gained 2.95% in 2022, then fell 26.17% in 2023.
• Over 4 years, Total Non-Current Liabilities stood at $33.5 million in 2022, then decreased by 25.39% to $25.0 million in 2023, then surged by 259.77% to $89.9 million in 2025, then retreated by 28.01% to $64.7 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $64.7 million, $89.9 million, and $87.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.